Advertisement

Parasitology Research

, Volume 114, Supplement 1, pp 165–174 | Cite as

Laboratory Evaluation of the Efficacy of 10 % Imidacloprid + 2.5 % Moxidectin Topical Solution (Advantage® Multi, Advocate®) for the Treatment of Dirofilaria immitis Circulating Microfilariae in Dogs

  • Dwight D. BowmanEmail author
  • Samuel D. Charles
  • Robert G. Arther
  • Terry Settje
Open Access
Original Article

Abstract

This study aimed to evaluate the efficacy of an emodepside 2.1 % (w/v)/praziquantel 8.6 % (w/v) topical solution (Profender® spot-on for cats) in the prevention of lactogenic Toxocara cati infections. A controlled test was performed with two groups of 8 cats with confirmed pregnancy. All cats were infected with daily doses of 2000 T. cati eggs for 10 consecutive days starting 50 days post conception to produce an acute infection. Treatment was performed 60 days post conception. Queens in the treatment group received the emodepside/praziquantel solution at the minimum therapeutic dose (3 mg/kg emodepside and 12 mg/kg praziquantel), while the control group was treated with a placebo spot-on. Efficacy was evaluated 56 days post partum by necropsy of one randomly selected kitten of each litter and comparison of the worm burdens between the study groups. Additionally the necropsy results were supported by quantification of worms expelled with the faeces after deworming of the remaining kittens and all queens. The treatment in late pregnancy resulted in an efficacy of 98.7 % (p < 0.0001). All necropsied control kittens were infected (geometric mean 30.6). Seven of 8 kittens from treated mothers were free of T. cati (geometric mean 0.4). Worm counts after deworming reflected the results obtained at necropsy. No side effects of the treatment were observed. It is concluded that treatment with an emodepside/praziquantel spot-on solution during late pregnancy effectively prevents lactogenic transmission of T. cati to the offspring. The study design facilitated the generation of reliable data, while at the same time a minimum number of animals was sacrificed.

Keywords

Imidacloprid Macrocyclic Lactone Moxidectin Emodepside Heartworm Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Al-Azzam SI, Fleckenstein L, Cheng KJ, Dzimanski MT, McCall JW (2007) Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. Biopharm Drug Dispos 28:431–438PubMedCrossRefGoogle Scholar
  2. American Heartworm Society 2014 Current canine guidelines for the diagnosis, prevention and management of heartworm (Dirofilaria immitis) infections in dogs. Available at http://www.heartwormsociety.org/veterinary-resources/canineguidelines.html#7
  3. Arther RG, Bowman DD, Slone RL, Travis LE (2005) Imidacloprid plus moxidectin topical solution for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasitology Res 97(suppl1):76–80CrossRefGoogle Scholar
  4. Blagburn BL, Dillon AR, Arther RG, Butler JM, Newton JC (2011) Comparative efficacy of four commercially available heartworm preventive products against the MP3 laboratory strain of Dirofilaria immitis. Vet Parasitology 176:189–194CrossRefGoogle Scholar
  5. Bowman DD (2009) Diagnostic Parasitology. In: Georgis’ Parasitology for Veterinarians, 9th Edition. Elsevier, St. Louis, pp 318Google Scholar
  6. Bowman DD, Atkins CE (2009) Heartworm biology, treatment and control. Vet Clin Small Anim 39:1127–1158CrossRefGoogle Scholar
  7. Bowman DD (2012) Heartworm, macrocyclic lactones, and the specter of resistance to prevention in the United States. Parasites and Vectors 5:138PubMedCentralPubMedCrossRefGoogle Scholar
  8. Cruthers LR, Arther RG, Basel CL, Charles SD, Hostetler JA, Settje TL (2008) New developments in parasite prevention. Bayer selected proceedings. NAVC 2008 Suppl Vet Forum 25(3B):15–20Google Scholar
  9. Geary TG, Mackenzie CD (2011) Progress and challenges in the discovery of macrofilaricidal drugs. Expert Rev Anti Infect Ther 9(8):681–695PubMedCrossRefGoogle Scholar
  10. Hellmann K, Heine J, Braun G, Paran-Dobesova R, Svobodava V (2011) Evaluation of the therapeutic and preventive efficacy of 2.5 % moxidectin/10 % imidacloprid (Advocate®. Bayer Animal Health) in dogs naturally infected or at risk of natural infection by Dirofilaria repens Parasitology Res 109(suppl1):77–86Google Scholar
  11. Hendrix CM, Blagburn BL, Bowles JV, Spano JS, Aguilar R (1992) The safety of moxidectin in dogs with microfilariae and adults of Dirofilaria immitis. In: Soll, MD (ed) Proceedings the American Heartworm Symposium Austin TX: pp 183 – 187Google Scholar
  12. Louisiana State University School of Veterinary Medicine, Heartworm disease. 2015 available at: http://www1.vetmed.lsu.edu/VTHC/Shared%20Services/Shared%20 Services/…/item41535.html
  13. McCall JW, Arther R, Davis W, Settje T (2014) Safety and efficacy of 10 % imidacloprid + 2.5 % moxidectin for the treatment of Dirofilaria immitis circulating microfilariae in experimentally infected dogs. Veterinary Parasitol 206:86–92CrossRefGoogle Scholar
  14. Prichard R, Roulet A (2005) Moxidectin Pharmacodynamics: Impact on resistance mechanisms to macrocyclic lactones in laboratory and field strains of nematode parasites. In: Moxidectin: Continued innovation in parasite control 20th WAAVP: pp 19 – 26Google Scholar
  15. Prichard R, Ménez C, Lespine A (2012) Moxidectin and the avermectins: Consanguinity but not identity. Int J Parasitol Drugs and Drug Resist 2:134–153CrossRefGoogle Scholar
  16. Traversa D, Aste G, Di Cesare A, Paoletti B, Di Tommaso M, Di Giulio E, Pampurini F, Tunesi C, Boari A (2011) Efficacy of a single administration of a spot-on solution containing imidacloprid 10 %/moxidectin 2.5 % in eliminating Dirofilaria repens microfilariae in naturally infected dogsGoogle Scholar

Copyright information

© The Author(s) 2015

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Dwight D. Bowman
    • 1
    Email author
  • Samuel D. Charles
    • 2
  • Robert G. Arther
    • 2
  • Terry Settje
    • 2
  1. 1.Cheri Hill Kennel & SupplyStanwoodUSA
  2. 2.Bayer HealthCare, Animal Health Division, Clinical Development DivisionShawneeUSA

Personalised recommendations